The average one-year price target for Century Therapeutics (NasdaqCM:IPSC) has been revised to $4.20 / share. This is an ...
Century Therapeutics (IPSC) aims at a durable “once-and-done” Type 1 diabetes cure with hypoimmune iPSC beta cells; runway to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results